Mavacamten

iStock, Yellow Man Braveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is looking to establish its name in the cardiometabolic space. Wednesday witnessed double initial public offerings, maintaining an upswing in biotech public debuts this year that have already more than doubled last year’s total. A third player joined the fray on Thursday, with Vogenx also launching its bid for the Nasdaq. This week, Braveheart Bio and Attovia Therapeutics, looking to stand up to industry giants and their blockbuster drugs, announced their intention to hit the public markets as they develop their pipelines in cardiovascular and immunology indications, respectively. Vogenx, meanwhile, is advancing a pipeline of cardiometabolic therapies. All three filings are still early, so none of the companieshave yet to specify how much money they expect to raise or when they plan to close their fundraising efforts. Braveheart will trade on the Nasdaq Global Market under the ticker BRVE, while Attovia will carry the symbol ATTO and Vogenx will be VOGX. ezstandalone.cmd.push(function () { ezstandalone.showAds(129); }); It’s a strong indicator for how the second half of 2026 could shape up, especially after H1 saw 18 biotechs debut on the public markets, including two record-setting raises in Kailera Therapeutics and Parabilis Medicines . Braveheart and Attovia join two other biotechs—Scribe Therapeutics and Kalohexis —that have filed plans this month to take the public plunge. Many of the newly public companies have performed well as the XBI trends upwards, recently hitting “pandemic peak levels” after a several year slump, according to an investor note from Truist Securities on July 7. Hair loss biotech Veradermics is a standout, having risen more than 600% since its February debut to $123.70 as of closing on July 15. Business Biotech IPOs surge in H1 of 2026, shattering records and doubling last year’s total After a sluggish 2025, biotech IPOs have roared back to life. Fueled by resilient stock performances and improving market sentiment, the total number of public debuts so far this year has already eclipsed 2025’s total. July 15, 2026 · 2 min read · Gabrielle Masson Read more Braveheart, Attovia and Vogenx are looking to cash in on this momentum. Braveheart is raising money for its lead asset BHB-1893, a small-molecule cardiac myosin blocker being tested for obstructive and non-obstructive hypertrophic cardiomyopathy (oHCM and nHCM). In its prospectus , Braveheart specifically expressed its intention to position BHB-1893 as “a new standard of care” in HCM, challenging Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo. Camzyos, indicated for symptomatic oHCM, grew 77% year-on-year to bring in $1.07 billion in 2025. Myqorzo was approved for the same indication in December last year . Licensed from China’s Jiangsu Hengrui Pharmaceuticals in September 2025 for up to $1.1 billion , Braveheart’s BHB-1893 suppresses the excessive contraction of heart muscles. The asset is designed to address what Braveheart calls the “LVEF cost” of current HCM therapies: a decrease in left ventricular ejection fraction, or a decline in pump function that can accompany improvements in obstruction. BHB-1893 is designed to sidestep the LVEF cost, according to Braveheart, pointing to clinical data generated by Hengrui to date that show “limited” reductions in LVEF. The IPO proceeds will help Braveheart push BHB-1893 through Phase 3 development for both oHCM and nHCM. Meanwhile, Attovia is looking to compete with Sanofi and Rgeneron’s blockbuster drug Dupixent. Attovia’s lead program is ATTO-1310, an anti-IL-31 therapeutic that the biotech plans to study for chronic pruritus of unknown origin (CPUO) and high-itch atopic dermatitis (AD), among other immune-driven indications, according to a securities filing . Dupixent is indicated for AD and made $17.8 billion last year. With ATTO-1310, Attovia hopes to address what it sees as current limitations in the AD space: inconvenient dosing, burdensome adverse events and a “remaining significant efficacy gap” in itch relief. The IPO proceeds will help Attovia advance ATTO-1310, as well as another candidate called ATTO-2306, which is designed to block IL-13 and IL-31 signaling, both implicated AD. The biotech also plans to study the asset in other immune-mediated skin conditions such as chronic spontaneous urticaria and prurigo nodularis. Attovia wants to start a Phase 1 program for ATTO-2306 in the first half of 2027, according to its prospectus. Rounding out the IPO trio is Vogenx, which is targeting diseases of dysfunctional metabolism. Its lead asset is the selective SGLT1 inhibitor mizagliflozin, being proposed for the treatment of post-bariatric hypoglycemia (PBH) and gastroparesis, according to the company’s prospectus . Its main competitors in these indications are Amylyx Pharmaceuticals and Vanda Pharmaceuticals, though neither have secured an FDA approval for their respective candidates. Vogenx plans to use much of its IPO proceeds to support the development of mizagliflozin in these indications, with activities ongoing for a Phase 2b PBH program and plans to launch a mid-stage gastroparesis study in 2027. Vogenx also has a preclinical asset called VGX-2875, which it plans to test for weight maintenance. In this space, the biotech could go up against some of the industry’s biggest players, including Eli Lilly and Novo Nordisk, according to the securities filing. The public proposals from Braveheart, Attovia and Vogenx would add to the surge of IPOs already seen this year, with at least 18 companies already going public—more than double last year’s low of eight . Most recently, secretive startup Kalohexis last week filed a confidential prospectus looking to raise money for its pipeline, including a mid-stage medicine for muscle wasting in cancer patients and a Phase 1 drug for obesity.

It appears Braveheart Bio isn’t going to let Big Pharma take away its freedom anytime soon, as the company is aiming for a Nasdaq listing to move its phase 3 cardiovascular drug. The Tuesday IPO filing did not say how much the company plans to raise, but Braveheart has applied to list under the ticker BRVE. The biotech plans to use the proceeds to advance BHB-1893, an oral cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy, or HCM. Braveheart is one of a growing number of companies benefiting from the drug development prowess of China’s Jiangsu Hengrui Pharmaceuticals. Braveheart’s lead asset was licensed from Hengrui in a $1 billion biobuck deal in 2025. Obesity-focused Kailera, which completed a record-breaking IPO earlier this year, was also built around assets licensed from Hengrui. Braveheart quickly followed the Hengrui licensing pact with a $185 million series A round backed by Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences. HCM is a genetic heart disease in which the heart muscle abnormally thickens, making it more difficult for the heart to pump blood and increasing the risk of arrhythmias and sudden cardiac death. Braveheart and Hengrui released phase 2 data for BHB-1893 in obstructive HCM, or oHCM, and nonobstructive HCM, or nHCM, earlier this year. A March release said the 42-patient oHCM study resulted in “rapid and substantial reductions in left ventricular outflow tract gradient (LVOT-G), an established measure of cardiac obstruction.” In May, Braveheart shared that the 84-patient nHCM study “resulted in improvements across biomarkers of cardiac wall stress and tissue injury, echocardiographic measures of diastolic function and cardiac structure, and patient-reported symptoms and exercise capacity.” Braveheart said it plans to initiate global phase 3 studies of BHB-1893 in both oHCM and nHCM, with the oHCM trial beginning in the second half of this year and the nHCM trial starting in the first half of 2027. Hengrui is already conducting a phase 3 trial of its version of the drug in China, and Braveheart says more than 250 participants have received BHB-1893 to date. The filing noted that Braveheart’s drug will compete with Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo in the cardiac myosin inhibitor class, as both drugs are approved for oHCM. There are no FDA-approved treatments for nHCM, though Cytokinetics reported in May that a phase 3 trial of Myqorzo in the disease met its dual primary endpoints. Braveheart says BHB-1893 could simplify what it describes as complex dosing and monitoring requirements. The company estimates that fewer than 20% of eligible oHCM patients have received targeted therapies and says the drug’s rapid onset of action and potential convenience could offer advantages over existing treatments. The public listing news from Braveheart follows a flurry of IPO announcements this year, including those from lipid-focused Scribe Therapeutics , sleep apnea specialist Apnimed and biologics biotech Attovia Therapeutics in the last 10 days. Braveheart President and CEO Travis Murdoch, M.D., who led HI-Bio’s sale to Biogen in 2024, described BHB-1893’s promise in a May release. “The rapid and meaningful responses across diastolic function, cardiac structure, biomarkers and clinical endpoints in this placebo-controlled study suggest that we may be engaging the underlying pathophysiology in a unique and direct way.”